Medication info
Mavilder W Plus Tablet

Mavilder W Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Sodium Alendronate Trihydrate›91.37mg / 1 tabletCholecalciferol Concentrate Powder›53.33mg / 1 tablet
Manufacturer / importer
Yuyu Pharmaceutical Co., Ltd.
Appearance
White to grayish-white rectangular tablet
Packaging
4 tablets (4 tablets/PTPX1)
Approval status
Active

MFDS item code 201307574 · Approved 2013.05.31 · Insurance code 644501910

Summary

Main use
Treatment of osteoporosis in postmenopausal women and men
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on clinical data from 4 years. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. In patients at low risk of fracture, discontinuation should be considered after 3~5 years of treatment. Patients who discontinue treatment should be regularly reassessed for fracture risk. Other beverages or foods, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Drug Interactions”). If food is consumed within 30 minutes after taking this medicine or at the same time, absorption of alendronate in the body may decrease, reducing its efficacy. Take this medicine as soon as you get up in the morning and swallow it with a sufficient amount of water (170∼230 mL) to help the medicine reach the stomach quickly and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after your first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these administration instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients with inadequate dietary intake of calcium and vitamin D should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine, taken once weekly, provides one week's supply of the daily amounts of 400 IU and 800 IU of vitamin D. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the following morning, then resume taking it on the originally scheduled day and continue once weekly thereafter. However, do not take 2 tablets on the same day. Use in older adults (65 years and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance of 35∼60 mL/min). However, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min), as there is insufficient clinical experience.
Child dose
Children and adolescents (under 18 years of age): The safety and efficacy in children and adolescents have not been established.

Ingredients

Manufacturer
Yuyu Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women and men

  • Osteoporosis
View approved original text

Used for the treatment of osteoporosis in postmenopausal women and men.

How to take

Adult dose

Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on clinical data from 4 years. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. In patients at low risk of fracture, discontinuation should be considered after 3~5 years of treatment. Patients who discontinue treatment should be regularly reassessed for fracture risk. Other beverages or foods, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Drug Interactions”). If food is consumed within 30 minutes after taking this medicine or at the same time, absorption of alendronate in the body may decrease, reducing its efficacy. Take this medicine as soon as you get up in the morning and swallow it with a sufficient amount of water (170∼230 mL) to help the medicine reach the stomach quickly and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after your first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these administration instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients with inadequate dietary intake of calcium and vitamin D should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine, taken once weekly, provides one week's supply of the daily amounts of 400 IU and 800 IU of vitamin D. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the following morning, then resume taking it on the originally scheduled day and continue once weekly thereafter. However, do not take 2 tablets on the same day. Use in older adults (65 years and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance of 35∼60 mL/min). However, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min), as there is insufficient clinical experience.

Child dose

Children and adolescents (under 18 years of age): The safety and efficacy in children and adolescents have not been established.

Precautions

This medication can cause irritation to the upper gastrointestinal tract mucosa, potentially leading to esophagitis, esophageal ulcers, or esophageal erosions. If symptoms such as esophageal problems, difficulty swallowing, pain behind the sternum, or heartburn develop, discontinue use immediately and consult a physician. Take this medication with a sufficient amount of water and do not lie down for at least 30 minutes after taking. Patients with esophageal diseases, those unable to sit upright or stand, and those with hypocalcemia should not take this medication. Caution is required for patients with upper gastrointestinal tract diseases such as gastritis, duodenitis, or ulcers. Gastrointestinal side effects such as abdominal pain, nausea, dyspepsia, constipation, diarrhea, acid reflux may occur, and consult a physician in case of symptoms. Nervous system symptoms such as muscle, bone, joint pain, headache, dizziness, and taste disturbances have also been reported. This medication may interfere with the absorption of calcium supplements or antacids, so a gap of at least 30 minutes should be maintained between doses. Use during pregnancy should be considered carefully due to risks to both the fetus and the mother, and caution is advised during breastfeeding. Not for use in children, and elderly patients or those with severely impaired kidney function should consult a physician before taking. In case of overdose, symptoms such as hypocalcemia and gastrointestinal irritation may occur, and immediate contact with a healthcare institution is necessary for appropriate measures. Take this medication in the morning on an empty stomach with sufficient water and do not lie down for at least 30 minutes after taking. This medication should not be chewed or sucked in the mouth, and caution should be taken to avoid lying down immediately after taking due to the risk of esophageal irritation. When dental treatment is necessary, it is important to consult healthcare professionals before and after treatment due to the risk of jaw osteonecrosis. During the course of this medication, ensure sufficient intake of calcium and vitamin D to maintain bone health. If any adverse symptoms occur during treatment, immediate consultation with a physician is necessary, and dose adjustments should be made as directed.

Side effects

esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, indigestion, constipation, diarrhea, flatulence, acid reflux, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, dysgeusia, rash, erythema, anastomotic ulcer, urticaria, angioedema, hypersensitivity reactions, myalgia, malaise, asthenia, fever, symptoms of hypocalcemia, peripheral edema, oral pharyngeal ulcer, osteomyelitis, jaw necrosis, joint swelling, low-energy fractures of the femoral head and other bones, itching, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external ear canal, nasopharyngitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container as it is sensitive to air and moisture. Keep at room temperature between 1 to 30 degrees, away from direct sunlight, preferably in a dark and cool place.

Appearance and packaging

Appearance

White to grayish-white rectangular tablet

Package unit

4 tablets (4 tablets/PTPX1)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.